azd5305 + carboplatin

AZD5305 + carboplatin is an investigational combination therapy comprising **AZD5305**, a next-generation, oral, highly selective **poly(ADP-ribose) polymerase 1 (PARP1) inhibitor** and trapper, together with **carboplatin**, a platinum-based chemotherapeutic agent. AZD5305 is designed for improved selectivity compared to first-generation PARP inhibitors that target both PARP1 and PARP2, aiming to reduce hematologic toxicities, especially when used in combination with chemotherapy. Preclinical studies in ovarian cancer and other solid tumors have shown that AZD5305 + carboplatin produces robust anticancer efficacy, superior tumor regression, enhanced impairment of metastasis, and improved survival relative to monotherapy or first-generation PARP inhibitors. The combination is being evaluated in clinical trials across several advanced solid tumor indications, including ovarian, breast, prostate, and pancreatic cancer, particularly in patients with homologous recombination repair deficiencies or BRCA mutations[1][2][3][4][5][7].

Other names

saruparib + carboplatin (AZD5305 is also known as saruparib[8])azd5305 and carboplatinazd-5305 and carboplatinazd 5305 and carboplatin